title: Chemotherapy in osteogenic sarcoma: the experience of the Pediatric Department of the Gustave Roussy Institute.
authors.forename: C
authors.initials: C
authors.lastname: Kalifa
authors.forename: H
authors.initials: H
authors.lastname: Razafindrakoto
authors.forename: G
authors.initials: G
authors.lastname: Vassal
authors.forename: G
authors.initials: G
authors.lastname: Contesso
authors.forename: D
authors.initials: D
authors.lastname: Vanel
authors.forename: V
authors.initials: V
authors.lastname: Edeline
authors.forename: D
authors.initials: D
authors.lastname: Valteau
authors.forename: J
authors.initials: J
authors.lastname: Lemerle
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide; D003609:Dactinomycin; D004317:Doxorubicin / Q000008:administration & dosage; D005240:Feasibility Studies; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D002955:Leucovorin; D008297:Male; D008727:Methotrexate; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine
chemical_list: D001761:Bleomycin; D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D002955:Leucovorin; D007069:Ifosfamide; D008727:Methotrexate